upcoming technologies in breath analysis and medicine. The major focus this year will be on medical applications in addition to environmental and bioterrorism issues.
Topics include:
• nitric oxide
• exhaled breath condensate
• electronic nose and sensor arrays
• mass spectrometry and
bench-top instrumentation
• cutting-edge sensor technologies
Medical applications include:
• asthma, COPD, pulmonary hypertension, and other respiratory diseases
• gastrointestinal diseases
• occupational diseases
• critical care
• cancer
The summit is the third annual scientific meeting of IABR. The first was held in Dornbirn, Austria, and last year's was held in Prague. This summit is a collaboration among the National Aeronautics and Space Administration, the Environmental Protection Agency, the Monell Chemical Senses Center, and the Electrochemical Society. Summit proceedings will be published in the newly established Journal of Breath Research.
For abstract submission details, registration and more information about the
Breath Analysis Summit, please visit clevelandclinicmeded.com/breath07. Fall 2007 | 3 and researcher Linus Pauling demonstrated that there is more to exhaled breath than the classic gases of nitrogen, oxygen, carbon dioxide and water vapor. Based on gas-liquid partition chromatography analysis, Pauling reported the presence of 250 substances in exhaled breath. With modern mass spectrometry (MS) and gas chromatography mass spectrometry (GC-MS) instruments, we can now identify more than 5,000 unique substances in exhaled breath. These substances include elemental gases like nitric oxide and carbon monoxide and a multitude of volatile organic compounds. Exhaled breath also carries aerosolized droplets that have other compounds dissolved in them.
We now have the ability to test for any and all of these components. Thanks to major breakthroughs in new technologies (infrared, electrochemical and chemiluminescence among them) and the availability of desktop mass spectrometers, the field of breath analysis has made considerable advances in the 21 st century. Several methods now are in, or about ready to enter, clinical use.
Commercially available analyzers can measure nitric oxide (NO) levels in exhaled breath to the parts per billion (ppb) range and carbon monoxide to the parts per million (ppm) range.
Desktop mass spectrometers can measure volatile compounds in breath down to the parts per trillion (ppt) range. Aerosolized droplets in exhaled breath can be captured by a variety of methods and analyzed for a wide range of biomarkers, from metabolic end products and proteins to a variety of cytokines and chemokines, and the possibilities continue to expand.
The standardization of sample collection methods was a major hurdle faced by our field as it transitioned from the laboratory to clinical testing. To advance, close collaboration between technical experts (who design devices for clinical applications) and medical experts (who need tests/biomarkers to help diagnose and monitor clinical problems) was required.
One example of a collaborative success is the measurement of exhaled NO for monitoring airway inflammation in asthma. The advent of chemiluminescence analyzers in the early 1990s allowed the detection of low (ppb) levels of NO in exhaled breath. This was quickly followed by the observation that patients with asthma had higher than normal levels of NO in their exhaled breath, which later was linked to eosinophilic airway inflammation. In 2003, the U.S. FDA approved the first desktop NO analyzer for monitoring airway inflammation in asthma. The use of exhaled NO to monitor asthma is useful for a few reasons: It is noninvasive, can be performed repeatedly and can be used in children and patients with severe airflow obstruction, where other techniques are difficult or impossible to perform.
Exhaled NO also may be more sensitive than currently available tests in detecting airway inflammation, which may allow more optimum therapy.
Our research contributed greatly to the understanding of the role of NO in the pathobiology, diagnosis and monitoring of asthma. As members of the American Thoracic Society / European Respiratory Society joint task force, we helped develop the standardized procedures for the measurement of exhaled NO. Our pulmonary medicine colleagues at Cleveland Clinic also are at the forefront of breath testing, involved in using newer sensor technologies like the electronic nose and sensor arrays for breath analysis to detect lung cancer (see article page 4).
Breath analysis offers a window to lung physiology and disease, and exhaled breath testing is becoming an increasingly important noninvasive diagnostic method that can be used to evaluate health and disease states in the lung and beyond.
Contact Dr. Raed Dweik at 216.445.5763 or dweikr@ccf.org, and Dr. Serpil Erzurum at 216.445.7191 or erzurus@ccf.org. As part of a Cleveland Clinic team of pulmonologists and oncologists, we have evaluated the ability of gaseous chemical sensing devices to detect lung cancer by analyzing exhaled breath. Prior study has suggested the pattern of chemicals in the breath, or volatile organic compounds, may be unique in individuals with lung cancer.
Previously, we described the use of a carbon polymer sensor system. The output from this system is a change in the conductivity of the sensors based on the chemicals in the breath that contact them. We also reported the use of a colorimetric sensor array. The sensor used in this system was composed of 36 colored dots impregnated on a disposable cartridge. The dots were made of chemically responsive compounds that change their color based on the pattern of chemicals with which they come in contact. We hypothesized that the pattern of color changes on the sensor would be unique in lung cancer subjects.
In our first study, smellprints were obtained on the exhaled breath of 14 individuals with bronchogenic carcinoma, 19 with alpha-1 antitrypsin deficiency (α1-ATD), six with chronic beryllium disease (CBD), and 20 healthy controls. Unlike α1-ATD and CBD, exhaled breath of lung cancer patients clustered distinctly from controls. This data indicated that the exhaled breath of lung cancer patients has distinct characteristics that can be identified with a carbon polymer sensor system.
Subsequently, a cancer prediction model was prospectively evaluated in a group of 52 individuals, 12 with and 40 without cancer. In the prospective study, exhaled breath analyses by the electronic nose showed 71.4 percent sensitivity (CI: 41.9 to 91.6) and 91.9 percent specificity (CI: 82.1 to 97.3) for the diagnosis of lung cancer.
Our most recent study included 143 subjects, of which 49 had lung cancer, 73 had a variety of lung diseases, and 21 were healthy controls. A model was developed using 70 percent of the study subjects' breath results. This model was tested on the remaining 30 percent of participants, where it was found to be 73.3 percent sensitive and 72.4 percent specific for the diagnosis of lung cancer.
These results support the potential for breath analysis to be developed into a useful diagnostic test for lung cancer, confirming previously performed work by us and others.
We hope to learn more about the unique constituents of the breath of lung cancer subjects and develop analysis systems that accurately screen for, and diagnose, lung cancer in a noninvasive manner. 
PUBLICATIONS

Colorimetric sensor array.
Sample of a color fingerprint demonstrating changes in color due to exposure to exhaled breath generated from a colorimetric sensor array. Surgical candidates will undergo an extrapleural pneumonectomy (en bloc removal of lung, pleura, pericardium and diaphragm) to ensure maximum cytoreduction.
The pericardium and diaphragm are reconstructed using GORE-TEX ® mesh to protect the heart and to prevent abdominal organ migration.
Eight weeks after surgery, patients begin a course of adjuvant chemoradiation.
Cisplatin is used to sensitize any remaining tumor cells, and a 3-D conformal radiotherapy beam is used to eradicate the residual tumor cells in the chest cavity.
This beam is a 45-gray dose of external radiation, computer gated to match the contours of the chest cavity and to minimize side effects.
Thus far, we have enrolled about 10 patients and are looking to recruit another 40 over the next two years.
To refer patients for the study, contact Dr. Sudish Murthy at 216.444.5640 or murthys1@ccf.org.
CME Calendar
Physicians are welcome to attend the following upcoming symposia: 
L i s T e d Pa T i e n T s C a n Wa i T a T H o M e
Any wait-listed transplant candidates within a 1,000-mile radius of Cleveland
Clinic can wait at home until a donor organ is located. Once a donor organ is found, patients are transported within hours via private plane to Cleveland. Endobronchial ultrasound (EBUS) is a new technology being used to evaluate airway, lung and lymph node abnormalities. EBUS offers pulmonologists and thoracic surgeons an improved ability to diagnose disease, stage cancer and determine which patients are candidates for surgery. The three general uses for intra-thoracic ultrasound include:
P e r i P H e r a L e n d o b r o n C H i a L U LT r a s o U n d ( P -e b U s )
To better evaluate peripheral lung lesions and increase diagnostic accuracy, we use a peripheral probe. A miniaturized probe is introduced through the working channel of the bronchoscope. The differences in density between the lung lesion and the normal lung architecture are highlighted as the probe is introduced into the abnormal area. A catheter is then left in place and samples are taken. Recent data suggest an improved yield using P-EBUS.
b a L L o o n P r o b e
Often it is difficult to distinguish between tumor invasion in an airway wall versus compression from outside the airway. To help differentiate an abnormal airway (airway involved with cancer) from a normal airway, we can insert an ultrasound probe, enveloped inside a balloon, into the airway. Once the balloon is inflated with saline, the ultrasonic image can show intrinsic (involved airway) from extrinsic (compression outside the airway) involvement. This technique can allow for improved detection of airway invasion and determine which patients are candidates for resection.
e n d o b r o n C H i a L U LT r a s o U n d T r a n s -b r o n C H i a L n e e d L e a s P i r aT i o n
The hybrid bronchoscope (convex probe or puncture scope) is currently being used to improve the diagnostic yield of transbronchial needle aspiration (TBNA). The endobronchial ultrasound TBNA scope is designed with a small ultrasound on the tip that allows visualization of the lymph nodes. The scope also features a needle for sampling.
The EBUS TBNA scope allows physicians to visualize the lymph nodes and vessels as well as see the needle puncture the lymph node in real-time, providing an improved recovery and a potentially safer procedure for the patient. Our current yield exceeds 94 percent using this technique. We currently are using the EBUS TBNA scope for minimally invasive mediastinal staging as well as initial diagnosis. We are adding a second EBUS TBNA scope so that we may serve more patients.
Contact Dr. Michael Machuzak at 216.444.2718 or machuzm@ccf.org; Dr. Thomas Gildea at 216.444.6490 or gildeat@ccf.org; and Dr. Atul Mehta at 216.444.2911 or mehtaa1@ccf.org. Pulmonary embolisms prove fatal when not diagnosed early and treated effectively. While the advent of thrombolytic therapy and catheter embolectomy have made emergent pulmonary thromboembolectomies rare procedures -roughly 10 are performed at Cleveland Clinic each year -they remain a lifesaving tool of last resort.
Two Pulmonologists Win Innovator Award
A 23-year-old female with a past medical history for Factor 5 Leiden mutation, deep vein thrombosis, pulmonary embolisms, hemolytic anemia, splenectomy, and an inferior venacava filter (placed because of recurrent pulmonary embolisms despite being on coumadin therapy), presented to an outside institution complaining of progressively worsening shortness of breath. Because of her condition and complicated medical background, she was emergently transferred to Cleveland Clinic for management. We initiated thrombolytic therapy, which resulted in a slight improvement in her hemodynamic parameters. However, the patient continued to require a considerable amount of supplemental oxygen to maintain adequate blood saturation, and she continued to show signs and symptoms of oxygen deprivation with clinically evident respiratory distress, tachycardia and an altered mental status. Her condition was critical. After a team consult, we decided to perform an emergent bilateral pulmonary thromboembolectomy.
The procedure was approached through a median sternotomy, and the patient was systemically heparinized. She underwent direct aortic and bicaval cannulation. The patient was placed on cardiopulmonary bypass and, with the aid of hypothermic circulatory arrest (HTCA), cooled to approximately 18° C. An exploration of her pulmonary arteries revealed a considerable amount of acute and chronic thrombus obstructing the previously described pulmonary artery. All thrombus burden was removed during intermittent periods of HTCA, and the pulmonary arteries were repaired using a patch technique.
The patient's postoperative period was unremarkable. On post-op day two, she was extubated and attempted to get out of bed and walk independently. She was weaned from the nasal cannula to room air within 10 days and remained in the hospital another four days until her anticoagulation was well controlled.
Since her hospital discharge, the patient has regained complete independence in her daily activities and currently suffers no limitation. An echocardiogram two months post-surgery revealed normal right ventricular function and no evidence of chronic pulmonary thromboembolism or pulmonary hypertension. Epidermal growth factor receptor (EGFR), a member of the tyrosine kinase receptor family, is known to play an important role in the cellular events of proliferation, differentiation and death in lung epithelial cells. When this receptor is over-expressed or mutated in non-small cell lung carcinoma, it can lead to a more aggressive clinical course and resistance to chemotherapy and radiotherapy.
Quantization and mutational analysis of wildtype EGFR in NSCLC may be helpful in In general, the most common method used in pathology laboratories is IHC, which applies an antibody to EGFR to microscopic slides of tissue samples. This quick and simple technique relies on easily available reagents and allows for quantization of the expression in the tumor. The reliability of this method depends upon the quality of the reagents, most notably the EGFR antibody used, and the preservation and viability of the tumor tissue being tested.
Fortunately, standardization of these reagents by the U.S. FDA has provided consistent methodology, resulting in a reliable method for inclusion of patients into clinical trials for use of anti-EGFR therapies.
FISH uses a fluorescence-labeled DNA probe to EGFR to measure its gene copy number in tumor cells. This ranges from no increase in copy number to polysomy to amplification.
The advantages of this methodology are similar to IHC, in that it can be used on archival formalin-fixed tissue samples and preserves tissue morphology. The relationship of gene copy number to protein expression and to prognosis and response to therapy is not known.
Some studies suggest that gene copy number may be better than protein expression in predicting prognosis. However, its high cost and added technical complexity needed to perform the test limit its widespread use.
The least well-developed technology uses sequencing to find activating mutations in the EGFR gene, because some studies have suggested that certain mutations confer a greater response rate to anti-EGFR therapy. This technology is challenging and requires larger amounts of tissue than normally contained in diagnostic lung biopsies, limiting its availability to only scattered laboratories throughout the country.
To date, the studies that have examined which of these methods is the most reliable in predicting prognosis or response to anti-EGFR therapies are inconclusive, since they have measured different end points (e.g., radiographic response versus time to progression versus overall survival). Clearly, the results of current prospective clinical trials will be needed to clarify the role of these new laboratory technologies.
Reach Dr. Carol Farver at 216.445.7695 Asthma generally is characterized by remodeling of the airway structure, including damage to airway epithelium, eosinophil infiltration, smooth muscle hyperplasia and basement membrane thickening. An increase in the number and size of vessels in the airway wall is a long-recognized occurrence and one of the most consistent features of asthma remodeling, occurring in mild, moderate and severe asthmatic lungs. According to the results of recent studies, angiogenesis occurs in chronic asthma, indicating a relation between the numbers of blood vessels in the bronchial wall and the severity of asthma.
Although an understanding of new vessel formation and its genesis in asthma is still in the early stages, it has been suggested that vascular remodeling may be a critical component in the pathophysiology of asthma.
Recently, endothelial progenitor cells (EPC) have been shown to play an essential role in the formation of new blood vessels. In adults, EPC are defined as a specific subset of bone marrow-derived cells with characteristics similar to those of embryonal angioblasts, i.e., the common hemopoietic and endothelial stem cells. The majority of EPC are believed to be bone marrow resident cells, of which only a minor fraction escape to circulate through the peripheral blood and contribute to the formation of new blood vessels and to vascular homeostasis.
In our study, the results of which were published this year in the Journal of Immunology, we hypothesized that angiogenesis is an early event with onset during the initiation of airway inflammation and is linked to the mobilization of bone marrow-derived EPC. We showed that asthmatic individuals have increased levels of circulating EPC that are highly proliferative and exhibit enhanced incorporation into tubes in an angiogenesis assay. In the experimental allergen challenge mouse model of asthma, EPC mobilization occurred as early as 24 hours after challenge and peaked at day eight. This was followed by an increase in microvessel density that progressed over time with chronic allergen exposure. In addition, the EPC remained elevated, even in the face of resolving inflammation.
Altogether, the data support the concept that EPC recruitment and an angiogenic switch are early events that occur during the derivation of allergic airway inflammation. These data also suggest that angiogenesis is not an epiphenomenon of chronic asthma but an early step in the onset of the disease in which highly proliferating and angiogenic potent EPC play an active role. 
P H U n i v e r s a L T i s s U e r e P o s i T o r y
The primary purpose of creating PHUTURE is to support research to uncover the etiology and pathogenesis of PH in pursuit of the ultimate goal of its treatment and cure. This study is enrolling patients with varying degrees of severity and various types of PH.
P H r e g i s T r y
The purpose of this registry is to collect demographic and clinical information as well as results of clinical testing performed on patients with PH as part of their routine clinical care. This registry includes all patients with PH seen within Cleveland Clinic's Pulmonary Vascular Program. No tests will be performed specifically for inclusion in the registry.
P H b r e a K T H r o U g H i n i T i a T i v e
This multicenter collaborative study is designed to 1) define the cellular basis of IPAH through the study of affected lung tissue; 2) describe the molecular pathways involved in the disease; and 3) identify genetic associations with the IPAH clinical phenotype.
n i T r i C o x i d e a n d C a r b o n M o n o x i d e i n P U L M o n a r y H y P e r T e n s i o n
This study evaluates the levels of NO and CO and their metabolites in patients with PH to gain a better understanding of the roles these biological markers play in the pathobiology of PH.
C L i n i C a L a n d P H y s i o L o g i C P r e d i C T o r s o f T r e a T M e n T r e s P o n s e i n P U L M o n a r y H y P e r T e n s i o n
This study evaluates new methods for monitoring PH patients over time using noninvasive tests like analysis of exhaled breath and peripheral vascular function.
M y e L o P e r o x i d a s e a s a b i o L o g i C M a r K e r i n P U L M o n a r y a r T e r i a L H y P e r T e n s i o n
This study aims to evaluate the potential role of MPO as well as other inflammatory and biological markers in evaluating the response to therapy in PAH.
i d i o Pa T H i C P U L M o n a r y a r T e r i a L H y P e r T e n s i o n
In pulmonary arterial hypertension, the pulmonary arteries have characteristic histopathology, These findings offer hope to develop new ways to measure progression of IPAH in patients as well as to develop novel therapies that will improve patient care for people who had few options before.
Pulmonary Hypertension Sponsored Studies
We are actively enrolling patients in the following trials: PI: Raed Dweik, M.D., 216.445.5763 To enroll a patient in REVEAL, 
